Research programme: cellular and protein based therapeutics - Celyad

Drug Profile

Research programme: cellular and protein based therapeutics - Celyad

Alternative Names: C3BS GQR 4; C3BS-GQR-1; C3BS-GQR-2; C3BS-GQR-3; C3BS-PQR-1

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Cardio3 BioSciences
  • Developer Celyad
  • Class Proteins; Stem cell therapies
  • Mechanism of Action Cell differentiation stimulants; Cell replacements; Stem cell stimulants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Myocardial infarction
  • Research Congenital heart defects
  • No development reported Heart failure

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Heart-failure in Belgium
  • 05 May 2015 Cardio3 BioSciences is now called Celyad
  • 07 Oct 2014 Early research in Congenital heart disorders in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top